KR20020019914A - 암치료용 ｅｔ743의 조성물 및 용도 - Google Patents

암치료용 ｅｔ743의 조성물 및 용도 Download PDF

Info

Publication number
KR20020019914A
KR20020019914A KR1020017014479A KR20017014479A KR20020019914A KR 20020019914 A KR20020019914 A KR 20020019914A KR 1020017014479 A KR1020017014479 A KR 1020017014479A KR 20017014479 A KR20017014479 A KR 20017014479A KR 20020019914 A KR20020019914 A KR 20020019914A
Authority
KR
South Korea
Prior art keywords
cancer
administering
patients
human patient
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020017014479A
Other languages
English (en)
Korean (ko)
Inventor
안젤라 바우만
에스테반 슈빗코빅
조지 다니엘 드미트리
세실리아 구즈만
호세 지메노
루이스 로페즈라자로
쟝 루이 미쎄
크리스 트웰브스
다니엘 디. 본호프
Original Assignee
추후제출
파르마 마르.에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by 추후제출, 파르마 마르.에스.에이. filed Critical 추후제출
Publication of KR20020019914A publication Critical patent/KR20020019914A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020017014479A 1999-05-13 2000-05-15 암치료용 ｅｔ743의 조성물 및 용도 Ceased KR20020019914A (ko)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB9911183.3 1999-05-13
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GB9911346.6 1999-05-14
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GB9918534.0 1999-08-05
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GB9927005.0 1999-11-15
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB9927106.6 1999-11-16
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
GB0007637.2 2000-03-29
PCT/GB2000/001857 WO2000069441A1 (en) 1999-05-13 2000-05-15 Compositions and uses of et743 for treating cancer

Publications (1)

Publication Number Publication Date
KR20020019914A true KR20020019914A (ko) 2002-03-13

Family

ID=27546594

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017014479A Ceased KR20020019914A (ko) 1999-05-13 2000-05-15 암치료용 ｅｔ743의 조성물 및 용도

Country Status (32)

Country Link
US (1) US8119638B2 (https=)
EP (3) EP1702618B1 (https=)
JP (2) JP2002544231A (https=)
KR (1) KR20020019914A (https=)
CN (2) CN100477993C (https=)
AR (1) AR028476A1 (https=)
AT (3) ATE375795T1 (https=)
AU (2) AU777417B2 (https=)
BG (1) BG65680B1 (https=)
BR (1) BR0010531A (https=)
CA (1) CA2373794C (https=)
CY (4) CY1105818T1 (https=)
CZ (1) CZ301482B6 (https=)
DE (4) DE60045720D1 (https=)
DK (3) DK1702618T3 (https=)
ES (2) ES2294756T3 (https=)
FR (1) FR08C0013I2 (https=)
HU (2) HU229866B1 (https=)
IL (2) IL146434A0 (https=)
LU (1) LU91418I2 (https=)
MX (1) MXPA01011562A (https=)
MY (1) MY164077A (https=)
NL (1) NL300337I2 (https=)
NO (2) NO324564B1 (https=)
NZ (1) NZ515423A (https=)
PL (1) PL198185B1 (https=)
PT (3) PT1702618E (https=)
SI (3) SI1176964T1 (https=)
SK (1) SK287580B6 (https=)
TR (1) TR200103819T2 (https=)
UA (1) UA74782C2 (https=)
WO (1) WO2000069441A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
HRP20080598T3 (en) * 2003-11-13 2009-01-31 Pharma Mar Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2006005602A2 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
CA3011527A1 (en) * 2016-02-04 2017-08-10 Jiangsu Hengrui Medicine Co., Ltd. Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and method for manufacturing the same
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
EP4353232A3 (en) 2020-04-15 2024-06-26 EVER Valinject GmbH Composition comprising trabectedin and an amino acid
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309477B1 (en) * 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
ATE493983T1 (de) * 1996-11-05 2011-01-15 Childrens Medical Center Thalidomide und dexamethason für die behandlung von tumors
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
CA2331593C (en) * 1998-05-11 2008-08-05 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
JP2004506430A (ja) * 2000-08-11 2004-03-04 シティ・オブ・ホープ Ｓｘｒによるトランス活性化の抗新生物剤ｅｔ−７４３による阻害
BR0115162A (pt) 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
WO2002078678A2 (en) 2001-03-30 2002-10-10 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
PL368458A1 (en) * 2001-10-19 2005-03-21 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
HRP20080598T3 (en) * 2003-11-13 2009-01-31 Pharma Mar Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2006005602A2 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
ES2361566T3 (es) * 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments

Also Published As

Publication number Publication date
LU91418I2 (fr) 2008-05-13
EP1702618A3 (en) 2006-12-27
HU229866B1 (en) 2014-10-28
TR200103819T2 (tr) 2002-04-22
ES2294756T3 (es) 2008-04-01
EP1716853A2 (en) 2006-11-02
DE60030554T2 (de) 2007-09-13
AU2005200180B2 (en) 2007-12-13
CY1107143T1 (el) 2010-07-28
DK1716853T3 (da) 2011-06-27
EP1716853B9 (en) 2011-09-28
CN1679631A (zh) 2005-10-12
NO20015516D0 (no) 2001-11-12
WO2000069441A1 (en) 2000-11-23
FR08C0013I2 (fr) 2009-10-30
EP1716853B1 (en) 2011-03-09
EP1176964B1 (en) 2006-09-06
EP1176964A1 (en) 2002-02-06
AR028476A1 (es) 2003-05-14
AU2005200180B9 (en) 2008-05-29
BR0010531A (pt) 2002-06-04
EP1176964B8 (en) 2007-10-10
US8119638B2 (en) 2012-02-21
CY2008007I2 (el) 2009-11-04
DK1702618T3 (da) 2008-02-25
SI1176964T1 (sl) 2007-02-28
PT1176964E (pt) 2007-01-31
NZ515423A (en) 2004-04-30
IL146434A0 (en) 2002-07-25
SI1716853T1 (sl) 2011-10-28
CY1105818T1 (el) 2011-02-02
JP2002544231A (ja) 2002-12-24
JP5777562B2 (ja) 2015-09-09
FR08C0013I1 (https=) 2008-05-30
EP1716853A3 (en) 2006-11-15
CA2373794C (en) 2005-10-11
NL300337I2 (nl) 2008-09-01
JP2012149095A (ja) 2012-08-09
PL352931A1 (en) 2003-09-22
DE60045720D1 (de) 2011-04-21
NO324564B1 (no) 2007-11-19
AU777417B2 (en) 2004-10-14
MY164077A (en) 2017-11-30
CN100477993C (zh) 2009-04-15
NL300337I1 (nl) 2008-05-01
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19
UA74782C2 (uk) 2006-02-15
NO2008005I2 (https=) 2010-09-27
IL146434A (en) 2008-03-20
CZ301482B6 (cs) 2010-03-17
DK1176964T3 (da) 2007-01-15
DE60036826T2 (de) 2008-08-28
SI1702618T1 (sl) 2008-02-29
PT1702618E (pt) 2008-01-11
CN1360503A (zh) 2002-07-24
CZ20014081A3 (cs) 2002-11-13
NO20015516L (no) 2002-01-11
ATE500830T1 (de) 2011-03-15
PT1716853E (pt) 2011-05-12
NO2008005I1 (no) 2008-06-09
EP1702618B1 (en) 2007-10-17
MXPA01011562A (es) 2002-07-30
SK287580B6 (sk) 2011-03-04
EP1702618A2 (en) 2006-09-20
DE122008000013I1 (de) 2008-08-07
DE60030554T8 (de) 2008-01-10
HUP0201187A2 (en) 2002-09-28
DE60036826D1 (de) 2007-11-29
CY2008007I1 (el) 2009-11-04
CA2373794A1 (en) 2000-11-23
BG106171A (en) 2002-06-28
US20070275942A1 (en) 2007-11-29
SK16442001A3 (sk) 2002-03-05
HUS1500001I1 (hu) 2016-08-29
CY1112753T1 (el) 2016-02-10
ATE375795T1 (de) 2007-11-15
ATE338552T1 (de) 2006-09-15
PL198185B1 (pl) 2008-06-30
BG65680B1 (bg) 2009-06-30
AU4597500A (en) 2000-12-05
HUP0201187A3 (en) 2002-11-28
LU91418I9 (https=) 2019-01-02
ES2272279T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
US8119638B2 (en) Compositions and uses of ET743 for treating cancer
RU2306933C2 (ru) Улучшенная схема применения противоопухолевого соединения в терапии рака
AU2002343548A1 (en) Improved use of antitumoral compound in cancer therapy
RU2266734C2 (ru) Композиции и применение ет743 для лечения злокачественных опухолей
ES2363064T3 (es) Tratamiento de cánceres del cuerpo humano utilizando et743.
NZ529801A (en) Compositions and uses of ET743 for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20011113

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050504

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060831

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20070901

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20060831

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20071203

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20070901

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080425

Appeal identifier: 2007101012290

Request date: 20071203

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20071203

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20071203

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070511

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20080114

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20071203

Effective date: 20080425

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20080425

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20071203

Decision date: 20080425

Appeal identifier: 2007101012290

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20080425

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20090717

Appeal identifier: 2008201008075

Request date: 20080628

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20080628

Effective date: 20090717

PJ1302 Judgment (patent court)

Patent event date: 20090724

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20080628

Decision date: 20090717

Appeal identifier: 2008201008075

Appeal kind category: Appeal against decision to decline refusal